Drugs / Haemophilus influenzae type b
Haemophilus influenzae type b
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00734565 | Jul → Oct 2008 | haemophilus infectious disease | Novartis Vaccines | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00327184 | Apr → Nov 2006 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06038617 | Oct 2023 → Apr 2025 | — | Duke University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03180359 | Jan 2016 → Oct 2019 | disease related to transplantation | Hospices Civils de Lyon | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06397768 Background | May 2024 → Sep 2025 | respiratory syncytial virus infectious disease | Sanofi Pasteur, a Sanofi Company | Terminated | No outcome recorded |
| Phase 3 | NCT00831753 Comparator | May 2008 → May 2009 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Haemophilus influenzae type b | “Pneumococcal, DTaP, Haemophilus Influenzae Type B, MMR, Varicella, MMRV, Hepatitis A, Inactivated Poliovirus, Hepatitis B, Rotavirus, Influenza vaccines” NCT06038617 ↗ |
| Known as | Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06397768 ↗ |
| Known as | DTaP-HB-IPV and Haemophilus influenzae type b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00831753 ↗ |
| Known as | Haemophilus influenzae type b- and meningococcal serogroup C (vaccine) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00327184 ↗ |
| Known as | Hib-MenC | “The purpose of this primary vaccination phase is to demonstrate the non-inferiority of two doses of Biologicals' Hib-MenC conjugate vaccine when given with Infanrix™ penta to...” NCT00327184 ↗ |
| Modality | Vaccine | “Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)” NCT00327184 ↗ |
| Route | Intramuscular | “Intramuscular” NCT00831753 ↗ |